Disclosed are compositions comprising polymeric nanoparticles and methods of using the same. The polymeric nanoparticles can be conjugated with a targeting ligand that is a substrate for a solid tumor-specific cell protein. The polymeric nanoparticles can also comprises an imaging compound and/or a therapeutic agent encapsulated in the hydrophobic interior of the nanoparticle. A cancer therapeutic composition comprising the nanoparticle is also disclosed. The disclosed nanoparticles can be used to target and deliver imaging and/or therapeutic compounds to cancer cells, thereby identifying and/or treating a solid tumor cell target. Methods for treating cancer, such as lung cancer, using the polymeric nanoparticles are also disclosed.

The field of the disclosure relates generally to cancer cell destruction and, more specifically, to cancer cell destruction by photo-magnetic irradiation mediated multimodal therapy using smart nanostructures.

The present application discloses nanoparticles carrying therapeutic agents, including chemotherapeutic agents, and targeting ligands suitable for delivering these therapeutic agents through the blood brain barrier and methods of using these patients on those patients in need of such treatment.

Disclosed herein are methods and agents for the treatment of cancer using p53-independent apoptosis to reduce the number of cancer cells that have an amplified HER2 gene, such as p53-depleted or p53-mutated cancer cells that have an amplified HER2 gene. Also disclosed herein are methods and agents for the treatment of HER2-positive cancer in individuals with Li-Fraumeni Syndrome.

Provided is a mitochondrial copper depleting strategy that exploits the potential vulnerability for this metabolic by cancer cells such as Triple Negative Breast Cancer cells. A nanoparticle is provided that comprises a self-reporting copper-depleting moiety (CDM) embedded in or on the matrix comprising a semi-conducting polymer and a phospholipid-polyethylene glycol (PEG). The positively charged copper-depleting complex targets mitochondria and deprives cytochrome c oxidase of its necessary copper co-factor. Inhibition of the electron transport chain complex IV compromises oxygen consumption and abrogates fatty acid oxidation, resulting in energy deficiency induced apoptosis of the targeted cancer cells. The copper-depleting nanoparticle can report the copper depleting status through multimodal optical signal changes while decreasing the copper level in tumors to inhibit tumor growth with low toxicity and significantly prolonged survival.

The present disclosure generally relates to nanoparticles comprising an antibody, such as an anti-PD-1 antibody. Other aspects include methods of making and using such nanoparticles. In an embodiment, the nanoparticles comprise a diblock poly(lactic) acid-poly(ethylene)glycol (PLA-PEG) copolymer, a chemotherapeutic agent, and a prostate-specific membrane antigen (PSMA) targeting ligand.

The present invention provides nanoparticle conjugates incorporating the self-assembling module diphenylalanine (FF) dipeptide into a bioactive moiety. The conjugate self-assembles to form distinct nanometric structures such as nanospheres. The present invention further provides nanoparticles formed by supramolecular co-assembly of the conjugates with a diphenylalanine (FF) dipeptide or analog thereof, to generate bioactive self-assembled nanostructures.

The methods of manufacture of a drug delivery composition. In some aspects, the methods include providing an organic phase, a biologically active ingredient, and an aqueous phase with a desirable pH (e.g., a pH at which the active ingredient has increased solubility in the aqueous phase compared to at neutral pH). After mixing of one or more of the aforementioned components, the resultant mixture is processed to provide the desired drug delivery composition.

In certain embodiments, this disclosure relates to VIP and VIP agonists, optionally conjugated to nanoparticles, for use in methods of treating inflammatory T cell-mediated diseases or conditions, e.g., treating or preventing GvHD. In certain embodiments, this disclosure relates to methods of pulmonary administration of VIP and VIP agonists, optionally conjugated to nanoparticles. In certain embodiments, this disclosure contemplates nanoparticles disclosed herein.

A multifunctional dendrimer nanoparticle and method of treating diseases of the posterior segment of the eye is presented. The functionalized polyamidoamine (PAMAM) dendrimer effectively delivers drugs and/or genes to the posterior eye, thereby providing for the effective, non-invasive, and topical treatment of diseased in the posterior eye. The multifunctional dendrimer nanoparticle has shRNA-encoding DNA and small molecule drug encapsulated cyclodextrin complexed to the outer surface of the dendrimer for delivery to the posterior segment of the eye.